generation run 2026-04-24
88 min completedmodel pipeline-v5plan not recordedrun/008b3e06…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- ashton_manual_not_directly_cited_in_prose
- taper_rate_not_substance_specific
Reproduce
- inputs
- 42 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
23 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | clonazepam pharmacokinetics human oral bioavailability elimination half-life | 1 | 0 | No new substance-specific PK studies found |
| 2 | PubMed | clonazepam cognitive effects memory impairment psychomotor performance | 1 | 1 | Direct measurement of clonazepam subjective/cognitive effects in controlled study |
| 3 | OpenAlex | clonazepam benzodiazepine pharmacology | 8 | 2 | Both contain clonazepam PK reference ranges and TDM data |
| 4 | PubChem | clonazepam | 1 | 1 | Primary chemical identity verification |
| 5 | PubMed | clonazepam anxiety disorder panic disorder treatment randomized controlled trial | 10 | 4 | Key clinical trial data for panic disorder indication and adverse effects |
| 6 | ClinicalTrials.gov | clonazepam | 10 | 1 | No active pivotal trials specifically for clonazepam found |
| 7 | PubMed | clonazepam pharmacokinetics bioavailability half-life metabolism human | 4 | 1 | Marginal pharmacokinetic relevance |
| 8 | PubMed | clonazepam overdose toxicity death case report | 3 | 2 | Relevant for safety/toxicity section |
| 9 | PubMed | clonazepam GABA-A receptor binding affinity pharmacology mechanism | 10 | 1 | Only paper with direct clonazepam binding data at recombinant GABA-A subtypes |
| 10 | PubMed | benzodiazepine tolerance GABA-A receptor downregulation mechanism | 8 | 5 | Mechanistic basis for tolerance development relevant to dependence section |
| 11 | PubMed | clonazepam REM sleep behavior disorder treatment efficacy | 7 | 2 | Clonazepam is AASM-recommended for RBD; direct efficacy evidence |
| 12 | PubMed | benzodiazepine withdrawal syndrome management diazepam taper seizure risk | 3 | 2 | BZD withdrawal management relevant for clonazepam dependence section |
| 13 | Multiple | clonazepam PK half-life synthesis history comparison | 5 | 3 | Cross-referencing PK data for accuracy in research output |
| 14 | Britannica/web | clonazepam history synthesis FDA | 1 | 1 | Historical context for article |
| 15 | StatPearls/NCBI Bookshelf | clonazepam complete pharmacology | 1 | 1 | Most comprehensive single-source pharmacology summary with clinical data |
| 16 | PubMed | clonazepam bipolar disorder mania acute treatment adjunctive | 6 | 3 | Off-label use in bipolar disorder/acute mania |
| 17 | WebSearch/Canada.ca/GOV.UK | clonazepam legal status UK Schedule 4 Australia Canada prescription | 10 | 3 | Legal status section in research output |
| 18 | PubMed | clonazepam pregnancy teratogenicity fetal effects neonatal | 3 | 2 | Contraindications: pregnancy/lactation safety data |
| 19 | ACS/web · absence | clonazepam history synthesis | 0 | 0 | Failed retrieval; data obtained from Britannica instead |
| 20 | Multiple | Seed data vs published sources comparison | 1 | 3 | Quality control cross-referencing |
| 21 | StatPearls/NCBI Bookshelf | clonazepam pharmacokinetics contraindications overdose | 1 | 1 | Most comprehensive clinical pharmacology reference accessed |
| 22 | PubMed | benzodiazepine opioid concomitant use mortality risk death cohort study | 6 | 2 | Quantified mortality risk for opioid+BZD interaction - critical safety data |
| 23 | WebSearch | clonazepam Australia Schedule 4 TGA Canada Schedule IV CDSA | 10 | 2 | Jurisdictional legal status coverage |
83 claims by section — every cited sentence, checked against its source
safety26 · 17 ok
Claim in safety — inconclusiveinconclusiveworking →
Memory impairment (anterograde amnesia) is pervasive at supratherapeutic doses and is clinically documented across the full duration of acute effectssupported
CLO affected memory and attention throughout study (6h) pmid:12353555
Morbidity relates to the duration and depth of unconsciousness rather than direct organ toxicitysupported
morbidity related to duration of unconsciousness j.ajem.2014.04.004
Polypharmacy overdoses are substantially more dangerous. A fatal case involved clonazepam combined with prazosin, ivabradine, and propranolol, producing severe bradycardia, hypotension, and respiratory failure requiring temporary cardiac pacing and lipid emulsion therapy. Opioid co-ingestion represents the single greatest mortality risk: continuous benzodiazepine plus opioid use carries an adjusted hazard ratio of 1.78 for 1-year all-cause mortality compared to opioids alone, with case-crossover data confirming elevated death risk from acute concomitant use.supported
22-year-old male intentionally consumed clonazepam, prazosin, ivabradine, propranolol; severe bradycardia, hypotension, respiratory failure; required temporary pacemaker and lipid emulsion therapy aam.aam_208_25
Polypharmacy overdoses are substantially more dangerous. A fatal case involved clonazepam combined with prazosin, ivabradine, and propranolol, producing severe bradycardia, hypotension, and respiratory failure requiring temporary cardiac pacing and lipid emulsion therapy. Opioid co-ingestion represents the single greatest mortality risk: continuous benzodiazepine plus opioid use carries an adjusted hazard ratio of 1.78 for 1-year all-cause mortality compared to opioids alone, with case-crossover data confirming elevated death risk from acute concomitant use.supported
continuous BZD use aHR=1.78 vs opioids only prp2.70215
Paradoxical reactions — irritability, agitation, rage — can occur particularly at high doses or in specific populations.supported
paradoxical manic-like behavior possible in susceptible patients; 8mg clonazepam; resolved after ECT and tapering pmid:1949970
Claim in safety — inconclusiveinconclusiveworking →
A systematic review and meta-analysis of 13 RCTs (994 patients) found significantly more adverse events in flumazenil-treated groups compared to placebo (RR 2.85), including supraventricular arrhythmia and convulsionssupported
Meta-analysis of 13 RCTs (994 patients); flumazenil significantly more adverse events than placebo; most common SAEs: supraventricular arrhythmia and convulsions bcpt.12434
Resedation occurs in approximately 30% of flumazenil-treated casessupported
flumazenil use: resedation occurs in ~30% of cases j.ajem.2014.04.004
Claim in safety — inconclusiveinconclusiveworking →
Experimental data from chronic diazepam exposure in middle-aged mice demonstrate impaired long-term potentiation and reduced dendritic spine density in hippocampal neurons.supported
Chronic DZP impairs spatial learning and LTP in middle-aged mice; reduced dendritic spine density in hippocampal CA1 and CA3 fnagi.2021.777404
A case report documented frank mania in a patient receiving 8 mg/day clonazepam.supported
Case report: 41-year-old with chronic schizophrenia developed manic episode on 8mg clonazepam pmid:1949970
Late third-trimester exposure carries risk of floppy infant syndrome — neonatal hypotonia, poor feeding, and respiratory distress — as well as neonatal withdrawal symptomssupported
late trimester use associated with floppy infant syndrome and neonatal withdrawal pmid:7881198
Claim in safety — inconclusiveinconclusiveworking →
Clonazepam is excreted into breast milk; although levels are generally low, neonatal metabolism is impaired and breastfeeding is best avoided.supported
Clonazepam excreted into breast milk; clonazepam among BZDs detected in breast milk pmid:7881198
This delusion of sobriety is directly documented: in a controlled study of 10 healthy volunteers receiving 3 mg clonazepam, subjects were disinhibited throughout the 6-hour assessment period and did not perceive their own impairmentsupported
10 healthy volunteers received 3mg CLO; CLO affected memory and attention throughout study (6h); subjects disinhibited and did not perceive own impairment pmid:12353555
Flumazenil slow infusion has been studied as an alternative detoxification method: one series of 29 high-dose benzodiazepine-dependent patients reported 53% abstinence at 6 months.supported
29 patients detoxified from high-dose BZD; 53% abstinent at 6 months j.psychres.2012.02.008
Claim in safety — inconclusiveinconclusiveworking →
Retrospective cohort data quantify the risk: continuous benzodiazepine plus opioid use increases 1-year all-cause mortality by 78% (aHR 1.78) versus opioids alonesupported
continuous BZD use aHR=1.78 vs opioids only prp2.70215
Claim in safety — inconclusiveinconclusiveworking →
CYP3A4 inducers reduce clonazepam plasma concentrations, potentially causing therapeutic failure: * Carbamazepine — potent CYP3A4 inducer; accelerates clonazepam metabolism to clinically relevant lower levels * Phenobarbital, phenytoin — similarly reduce clonazepam levels via CYP enzyme induction * Rifampicin, St. John's Wort — class-level CYP3A4 inducers expected to reduce clonazepam exposuresupported
Carbamazepine is a potent CYP3A4 inducer; accelerates metabolism of clonazepam and other AEDs; can reduce plasma concentrations to clinically relevant extent pmid:8877250
Claim in safety — inconclusiveinconclusiveworking →
Felbamate does not produce clinically relevant pharmacokinetic interaction with clonazepam.supported
No clinically relevant pharmacokinetic interactions noted between felbamate and clonazepam pmid:9314612
Pregnancy — especially first and third trimesters; risk of congenital abnormalities and floppy infant syndromepartially supported
late trimester use associated with floppy infant syndrome and neonatal withdrawal pmid:7881198
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
summary11 · 6 ok
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Clonazepam acts as a positive allosteric modulator of GABA-A receptors, binding the benzodiazepine site at the α/γ subunit interface and increasing the frequency of chloride channel opening in response to GABAsupported
Reviews GABA-A receptor subunit pharmacology; 1,4-BZDs like clonazepam compared to 1,5-BZD clobazam 11599020-000000000-00000
Claim in summary — inconclusiveinconclusiveworking →
It binds α₁ and α₂ subunit-containing complexes with similar affinity — this non-selectivity underlies its broad profile spanning sedation (α₁-mediated), anxiolysis (α₂-mediated), anticonvulsant, and myorelaxant effectssupported
Clonazepam (CLN) shows no distinction between α2 and α1 receptor complexes, unlike clobazam journal.pone.0088456
Critically, users do not perceive their own impairment — a phenomenon documented as delusions of sobrietysupported
subjects disinhibited and did not perceive own impairment pmid:12353555
Acute toxicity of clonazepam alone is low owing to the wide therapeutic index characteristic of benzodiazepines; serious morbidity and fatality concentrate in polydrug overdoses, particularly opioid co-ingestion (adjusted hazard ratio 1.78 for 1-year mortality vs. opioids alone)supported
continuous BZD use aHR=1.78 vs opioids only prp2.70215
Physical dependence develops with regular use via a well-characterized cascade: GABA-A receptor internalization through PLC-δ/Ca²⁺/calcineurin signaling, α₁ subunit transcriptional downregulation, and compensatory glutamatergic sensitizationsupported
Prolonged diazepam exposure disrupts inhibitory GABAergic synapses via GABAR internalization through PLCδ/Ca2+/calcineurin pathway s41380-018-0100-y
Physical dependence develops with regular use via a well-characterized cascade: GABA-A receptor internalization through PLC-δ/Ca²⁺/calcineurin signaling, α₁ subunit transcriptional downregulation, and compensatory glutamatergic sensitizationsupported
Chronic benzodiazepine exposure downregulates GABA-A α1 subunit gene via L-type VGCCs; mechanism underlying tolerance j.neulet.2020.134801
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
pharmacology10 · 8 ok
This allosteric potentiation increases chloride conductance, producing neuronal hyperpolarization and reduced excitability throughout the CNS.supported
Reviews GABA-A receptor subunit pharmacology; 1,4-BZDs like clonazepam compared to 1,5-BZD clobazam 11599020-000000000-00000
Claim in pharmacology — inconclusiveinconclusiveworking →
α₁-containing receptors — mediate sedation, hypnosis, anticonvulsant activity, and anterograde amnesiasupported
α1 mediates sedation/amnesia, α subunits involved in anticonvulsant activity 11599020-000000000-00000
α₂-containing receptors — mediate anxiolytic effectssupported
α2 mediates anxiolysis 11599020-000000000-00000
Clonazepam does not display meaningful selectivity between α₁ and α₂ receptor complexes — it binds both with similar affinity in native rat-brain membrane preparations and cloned receptor systems expressed in HEK293 cellssupported
Clonazepam (CLN) shows no distinction between α2 and α1 receptor complexes, unlike clobazam; clonazepam tested in native rat-brain and HEK293 cloned receptors journal.pone.0088456
Claim in pharmacology — inconclusiveinconclusiveworking →
Clonazepam is well absorbed after oral administration, with bioavailability estimated at approximately 90% (≥80% per early pharmacokinetic characterization)supported
oral absorption 80%+ pmid:2822672
The elimination half-life ranges from 20 to 80 hours, with a population mean of 30–40 hourssupported
Clonazepam elimination half-life 20-80 hours pmid:2822672
Neither the amino- nor the acetamido-metabolite possesses meaningful pharmacological activitysupported
amino/acetamido metabolites pharmacologically inactive pmid:2822672
The drug disappears in parallel from both compartments with no evidence of sequestration or accumulation in brain tissue.supported
brain:plasma concentration ratio constant pmid:2822672
clinical-evidence9 · 4 ok
Claim in clinical-evidence — inconclusiveinconclusiveworking →
A 3-year naturalistic extension study (n=47, clonazepam maintained at 1.9 mg/day mean dose) demonstrated significantly better CGI-Improvement scores with clonazepam versus paroxetine, with both treatments showing similar efficacy for panic attack reduction and anxiety severitysupported
3-year long-term study (n=47 clonazepam, n=37 paroxetine); target dose 2mg/d clonazepam; clonazepam showed significantly better CGI improvement and fewer adverse events than paroxetine jcp.0b013e31823fe4bd
Clonazepam has demonstrated efficacy for restless legs syndrome and neuroleptic-induced akathisia at doses of 0.5–3 mg in polysomnographic studies.supported
0.5-3mg clonazepam improved RLS symptoms in 17/18 patients and akathisia in 4/4 patients; reduced PLM on polysomnography pmid:9538563
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Early controlled data compared clonazepam to lithium and haloperidol for acute maniasupported
Double-blind studies comparing clonazepam with lithium and haloperidol in acute mania pmid:3312180
A retrospective cohort study examined adjunctive clonazepam as a potential neuroleptic substitute in bipolar maintenance therapy.supported
Retrospective review of 20 patients; clonazepam successfully replaced neuroleptic in 6/17 patients on combined lithium+neuroleptic pmid:2106533
neuroscience9 · 6 ok
Claim in neuroscience — inconclusiveinconclusiveworking →
The anxiolytic effects of benzodiazepines are mediated primarily through α₂-containing GABA-A receptors concentrated in limbic structuressupported
α2 mediates anxiolysis 11599020-000000000-00000
This mechanism is pharmacologically validated: clonazepam suppresses panicogenic responses in CO₂-challenge models, confirming direct engagement of panic circuitry.supported
clonazepam both decreased escape expression during CO2 challenge in mice; clonazepam treatment in human PD patients reduced CO2-induced panic attack severity; confirms clonazepam panicolytic activity via CO2 challenge model s41398-026-03836-7
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
This leads to gradual disassembly of inhibitory synapses — GABAergic synaptic contacts are physically lost, not merely desensitizedsupported
Prolonged diazepam exposure disrupts inhibitory GABAergic synapses via GABAR internalization through PLCδ/Ca2+/calcineurin pathway s41380-018-0100-y
Calcium influx appears to be the initiating event, and the PKA signaling cascade represents a separate mechanism from the calcineurin-mediated internalizationsupported
Chronic benzodiazepine exposure downregulates GABA-A α1 subunit gene via L-type VGCCs j.neulet.2020.134801
Calcium influx appears to be the initiating event, and the PKA signaling cascade represents a separate mechanism from the calcineurin-mediated internalizationsupported
Diazepam induces downregulation of GABA-A alpha1 subunit via L-VGCC/Ca2+/PKA/CREB-ICER pathway j.neulet.2023.137358
Stage 3 — Gephyrin scaffold destabilization. Chronic benzodiazepine treatment triggers shrinkage of gephyrin scaffolds — the submembranous protein platforms that anchor GABA-A receptors at synaptic sites. γ₂-containing GABA-A receptors accumulate extrasynaptically, reducing the efficiency of inhibitory neurotransmission at a nanoscale organizational level.partially supported
gephyrin scaffold smaller and inhibitory postsynaptic area diminished; γ2-GABA-A receptors condense into smaller synaptic areas; gephyrin downregulation via phosphorylation and protease cleavage fncel.2025.1624813
comparative-pharmacology5 · 3 ok
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Data derived from competitive binding studies in native rat-brain and cloned HEK293 preparationssupported
clonazepam tested in native rat-brain and HEK293 cloned receptors journal.pone.0088456
Half-life: Both have long elimination half-lives (clonazepam 30–40 h; diazepam 20–100 h including active metabolites), but diazepam produces long-lived active metabolites (desmethyldiazepam, t½ ~100 h) whereas clonazepam's metabolites are pharmacologically inactivesupported
Clonazepam elimination half-life 20-80 hours; amino/acetamido metabolites pharmacologically inactive pmid:2822672
Long-term (3 years): Clonazepam showed significantly better CGI-Improvement scores. Adverse events: 28.9% (clonazepam) vs. 70.6% (paroxetine)supported
clonazepam showed significantly better CGI improvement and fewer adverse events than paroxetine jcp.0b013e31823fe4bd
history4 · 2 ok
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
The American Academy of Sleep Medicine recommends it for REM sleep behavior disorder, and it is used off-label for restless legs syndrome, neuroleptic-induced akathisia, and acute mania in bipolar disordersupported
Summarizes evidence for clonazepam as one of four agents recommended by AASM for RBD j.sleep.2025.106554
The American Academy of Sleep Medicine recommends it for REM sleep behavior disorder, and it is used off-label for restless legs syndrome, neuroleptic-induced akathisia, and acute mania in bipolar disordersupported
Double-blind studies comparing clonazepam with lithium and haloperidol in acute mania; effective as adjunctive in lithium-resistant bipolar pmid:3312180
pharmacokinetic-detail4 · 3 ok
Neither metabolite retains clinically meaningful pharmacological activity at GABA-A receptors.supported
amino/acetamido metabolites pharmacologically inactive pmid:2822672
After a single dose, it is detectable in urine from approximately 12 hours post-dose, reaches peak concentration at 24 hours, and remains detectable to 72 hourssupported
7-aminoclonazepam first detected at 12h post-dose, peaked at 24h (54.61 ng/mL), remained detectable up to 72h post single dose bio.70049
Following repeated chronic dosing, 7-aminoclonazepam is detectable for 9 or more days — and potentially 2–3 weeks — after cessation of daily use.supported
7-aminoclonazepam detectable for 9+ days in urine; estimated 2-3 weeks detection after cessation of chronic use j.forsciint.2012.06.018
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
receptor-pharmacology4 · 2 ok
Clonazepam exhibits relatively high molar affinity for the benzodiazepine binding site on GABA-A receptorssupported
high molar affinity for BZ receptor pmid:2822672
Comparative binding studies confirm that clonazepam binds α₁- and α₂-containing GABA-A receptor complexes with similar affinity in both native rat-brain membrane preparations and cloned human receptor subtypes expressed in HEK293 cellssupported
Clonazepam (CLN) shows no distinction between α2 and α1 receptor complexes; clonazepam tested in native rat-brain and HEK293 cloned receptors journal.pone.0088456
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
chemistry1 · 0 ok
Claim in chemistry — inconclusiveinconclusiveworking →